These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 15892597)

  • 1. Design and analysis of phase III trials with ordered outcome scales: the concept of the sliding dichotomy.
    Murray GD; Barer D; Choi S; Fernandes H; Gregson B; Lees KR; Maas AI; Marmarou A; Mendelow AD; Steyerberg EW; Taylor GS; Teasdale GM; Weir CJ
    J Neurotrauma; 2005 May; 22(5):511-7. PubMed ID: 15892597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative study of outcome measures and analysis methods for traumatic brain injury trials.
    Alali AS; Vavrek D; Barber J; Dikmen S; Nathens AB; Temkin NR
    J Neurotrauma; 2015 Apr; 32(8):581-9. PubMed ID: 25317951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sliding Scoring of the Glasgow Outcome Scale-Extended as Primary Outcome in Traumatic Brain Injury Trials.
    Yeatts SD; Martin RH; Meurer W; Silbergleit R; Rockswold GL; Barsan WG; Korley FK; Wright DW; Gajewski BJ
    J Neurotrauma; 2020 Dec; 37(24):2674-2679. PubMed ID: 32664792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does the sliding dichotomy result in higher powered clinical trials for stroke and traumatic brain injury research?
    Price M; Hertzberg V; Wright DW
    Clin Trials; 2013; 10(6):924-34. PubMed ID: 23027647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical trials in traumatic brain injury: current problems and future solutions.
    Maas AI; Marmarou A; Murray GD; Steyerberg EW
    Acta Neurochir Suppl; 2004; 89():113-8. PubMed ID: 15335110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
    Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
    Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of designs for clinical trials of neuroprotective agents in head injury. European Brain Injury Consortium.
    Machado SG; Murray GD; Teasdale GM
    J Neurotrauma; 1999 Dec; 16(12):1131-8. PubMed ID: 10619192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase III Preclinical Trials in Translational Stroke Research: Community Response on Framework and Guidelines.
    Boltze J; Wagner DC; Henninger N; Plesnila N; Ayata C
    Transl Stroke Res; 2016 Aug; 7(4):241-7. PubMed ID: 27297402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Applying a phase II futility study design to therapeutic stroke trials.
    Palesch YY; Tilley BC; Sackett DL; Johnston KC; Woolson R
    Stroke; 2005 Nov; 36(11):2410-4. PubMed ID: 16224086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. To phase 3 or not to phase 3?
    Wasiewski WW
    Stroke; 2009 May; 40(5):1553-4. PubMed ID: 19286574
    [No Abstract]   [Full Text] [Related]  

  • 11. Have randomized controlled trials of neuroprotective drugs been underpowered? An illustration of three statistical principles.
    Samsa GP; Matchar DB
    Stroke; 2001 Mar; 32(3):669-74. PubMed ID: 11239185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decision making from Phase II to Phase III and the probability of success: reassured by "assurance"?
    Carroll KJ
    J Biopharm Stat; 2013; 23(5):1188-200. PubMed ID: 23957523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A method to determine stroke trial success using multidimensional pooled control functions.
    Mandava P; Kent TA
    Stroke; 2009 May; 40(5):1803-10. PubMed ID: 19286598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect Size Estimates for the ESCAPE Trial: Proportional Odds Regression Versus Other Statistical Methods.
    Sajobi TT; Zhang Y; Menon BK; Goyal M; Demchuk AM; Broderick JP; Hill MD
    Stroke; 2015 Jul; 46(7):1800-5. PubMed ID: 26022639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A simulation study evaluating approaches to the analysis of ordinal outcome data in randomized controlled trials in traumatic brain injury: results from the IMPACT Project.
    McHugh GS; Butcher I; Steyerberg EW; Marmarou A; Lu J; Lingsma HF; Weir J; Maas AI; Murray GD
    Clin Trials; 2010 Feb; 7(1):44-57. PubMed ID: 20156956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase III trials of targeted anticancer therapies: redesigning the concept.
    Ocana A; Amir E; Vera-Badillo F; Seruga B; Tannock IF
    Clin Cancer Res; 2013 Sep; 19(18):4931-40. PubMed ID: 23881926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel methodologic approaches to phase I, II, and III trials.
    Yeatts SD
    Stroke; 2013 Jun; 44(6 Suppl 1):S116-8. PubMed ID: 23709704
    [No Abstract]   [Full Text] [Related]  

  • 18. Targeting neuroprotection clinical trials to ischemic stroke patients with potential to benefit from therapy.
    Weir CJ; Kaste M; Lees KR;
    Stroke; 2004 Sep; 35(9):2111-6. PubMed ID: 15243146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel endpoints and design of early clinical trials.
    Parulekar WR; Eisenhauer EA
    Ann Oncol; 2002; 13 Suppl 4():139-43. PubMed ID: 12401680
    [No Abstract]   [Full Text] [Related]  

  • 20. Assessing outcome in head injury trials.
    Wilson JT
    Curr Pharm Des; 2001 Oct; 7(15):1537-52. PubMed ID: 11562298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.